Seres Therapeutics, Inc. (MCRB) — DEFA14A Filings
All DEFA14A filings from Seres Therapeutics, Inc.. Browse 3 DEFA14A reports with AI-powered summaries and risk analysis.
DEFA14A Filings (3)
-
Seres Therapeutics DEFA14A: Executive Compensation Details
— Apr 4, 2025 Risk: low
Seres Therapeutics, Inc. filed a DEFA14A on April 4, 2025, detailing executive compensation and related matters for the fiscal year ending December 31, 2024. Th -
Seres Therapeutics Proxy Filing: Earnings Call Solicitation
— Aug 13, 2024 Risk: low
Seres Therapeutics, Inc. filed a DEFA14A, indicating it is a definitive proxy statement soliciting material under Rule 14a-12. The filing pertains to their earn -
Seres Therapeutics Files Proxy Statement
— Aug 7, 2024 Risk: low
Seres Therapeutics, Inc. filed a DEFA14A on August 6, 2024, indicating it is soliciting materials under Rule 14a-12. The company, formerly known as Seres Health
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX